TY - JOUR
T1 - Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy
AU - Mazza, Camille
AU - Remon, Jordi
AU - Honoré, Charles
AU - Besse, Benjamin
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Thymomas are rare (1,5 cases/million) and typically occur in adults with a median age of 50 years old. Thymomas are indolent with a 10-year overall survival for resected stage II thymomas of 70%. Late relapses occur in 20% of the cases, and distant metastasis from thymoma is rare. Peritoneal recurrence of thymoma treated with surgery associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has not been described in the literature. This report manages peritoneal recurrence of thymoma with HIPEC, suggesting that aggressive therapies may decrease the risk of recurrence.
AB - Thymomas are rare (1,5 cases/million) and typically occur in adults with a median age of 50 years old. Thymomas are indolent with a 10-year overall survival for resected stage II thymomas of 70%. Late relapses occur in 20% of the cases, and distant metastasis from thymoma is rare. Peritoneal recurrence of thymoma treated with surgery associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has not been described in the literature. This report manages peritoneal recurrence of thymoma with HIPEC, suggesting that aggressive therapies may decrease the risk of recurrence.
KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)
KW - Peritoneal recurrence
KW - Thymoma
UR - http://www.scopus.com/inward/record.url?scp=85022216666&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2017.06.011
DO - 10.1016/j.lungcan.2017.06.011
M3 - Article
C2 - 28838398
AN - SCOPUS:85022216666
SN - 0169-5002
VL - 111
SP - 59
EP - 60
JO - Lung Cancer
JF - Lung Cancer
ER -